Связь гипергомоцистеинемии с интенсивностью повреждения эндотелия с выраженностью воспалительной реакции при кардиохирургических вмешательствах у больных с ишемической болезнью сердца
Диссертация
Установлено, что после хирургической реваскулярнзацнн миокарда в условиях ПК в обеих группах больных ИБС (основной и в группе сравнения) наблюдается значительный прирост в крови уровня ИЛ-6 и СРБТак у больных первой группы (получавших препарат «Ангновит») уровень провоспалнтельных медиаторов, спустя сутки после АКШ, возрос, в среднем в 4 раза (р<0,001). спустя трое суток, в среднем n 5 раз… Читать ещё >
Список литературы
- Алексеева И.А., Лякишев А. А., Ткачук В. А., Добровольский А. Б., Насонов Е. Н., Наумов В. Г., Парфенова Е. В. Белки острой фазы и рецидив стенокардии после успешной коронарной ангиопластики // Тер. Архив. 2002.34.c42- 46.
- Арефьева Т.И., Проваторов И., Самко А. Н., Байдун Л. В., Красникова Г. Л. Увеличение экспрессии моноцитарных молекул адгезии и образования мо- ноцит-тромбоцитарных агрегатов в крови при коронарном рестенозе // Тер. Архив. 2002.34.C.46−49.
- Баркаган З.С. Клинико-патогенетические варианты, номенклатура и основы диагностики гематогенных тромбофилий // Прообл. гематол. 1996.№ 3. с.5−15.
- Баркаган З. С, Цывкина Л. П., Костюченко Г. И., Момот А. П. Классификация, молекулярные механизмы и новые методы диагностики тромбофилий.// Бюлл. СО РАМН 2002.№ 2. с.51−55.
- Баркаган З. С, Костюченко Г. И., Котовщикова Е. Ф. Гипергомоцистеи- немия как самостоятельный фактор риска поражения и тромбирования кровеносных сосудов. // Патология кровообращения и кардиохирургия. — 2002. — № 1. -С. 65−71.
- Ефимов B.C., Кудрин B.C. Определение клинически значимых концентраций гомоцистеина путем использования стекло-углеродного электрода в электрохимическом детекторе методом ВЭЖХ. //Тромбоз, гемостаз и реология. 2О00.№ 3. с.39−41.
- Затейщиков А.А., Затейщиков Д. А. Эндотелиальная регуляция сосудистого тонуса: методы исследования и клиническое значение.// Кардиология. 1998. № 9.С68−81.
- Костюченко Г. И. Гипергомоцистеинемия при коронарной болезни сердца в условиях Западной Сибири (частота, выраженность, связь с маркерами повреждения эндотелия и воспаления, методы фармакологической коррекции) Дисс. докт. мед наук., Барнаул, 2004.
- Климов А.Н., Никуличеева Н. Г. Липиды, липопротеиды и атеросклероз. //Санкт-Персрбург Питер. 1995. с. 298.
- Кожеева А.З., Ефимов B.C. Гемокоагуляционный аспект развития ги- пергомоцистеинемии // Тромбоз, гемостаз и реология. 2000. № 4.с.32−34.
- Клюквина Т.Л., Баранов А. А., Александрова Е. Н., Насонов Е. Л. С- реактивный белок при системной красной волчанке: связь с тромботическими осложнениями. //Клин.мед 1997.№ 38.с.24−27.
- Либов И.А., Бабаев Э. К., Гультикова О. С. Новые аспекты развития нарушений липидного обмена и перспективы их коррекции. //Лечащий врач.- 2001. Jfe7.c4−8.
- Оглобина ОТ. Биохимичесчкие механизмы участия нейтрофилов в реакциях острого воспаления.//Вопр. мед. химии.1998.№ 5.с.2−9.
- Ольбинская Л.И., Игнатенко СБ. Роль цитокиновой агрессии в патогенезе синдрома сердечной кахексии у больных хронической сердечной недостаточностью. // Сердечная недостаточность. 2001.№ 3.с.132−135.
- Павликова Е.П., Мерай И. А. Клиническое значение интерлейкина-6 фактора некроза опухоли, а при ишемическои болезни сердца // Кардиология. № 8. 2003, с.68−72.
- Пиорала К Предшественники атеросклероза у детей — возможности профилактики: факторы и гипотезы. //Тер. арх. 1985.№ 11. с.26−29.
- Панов А. В. Лаевская М.Ю. Сахарный диабет типа 2 и атеросклероз: тактика гиполипидемической терапии. Consilium Medicum.2002.№l I .с.560- 564.
- Сидоренко Г. И. Мойсенок А.Г., Колядко М. Г. и др. Роль гомоцистеи- на в тромбо- и атерогенезе. Возможности и перспективы витаминной коррекции.// Кардиология. -200. № 3 -.С. 56−61.
- Фролова Т.А., Гильмиярова Ф. Н., Костричева Л. В. Клинико- генеалогическая оценка показателей холестерина и р-липопротеидов у детей с отягощенной по атеросклерозу наследственностью. //Педиатрия. 1984.№ 4. с.51- 52.
- Шмелева В.М. Гипергомоцистеинемия и тромбоз. //Тромбоз, гемостаз и реология. — 2000. — № 4. 26−29.
- Якобсон Г. С., Куимов А. Д., Антонов А. Р., Николаева А. А. Стресс, артериальная гипертензия, инфаркт миокарда.// Новосимбирск. 1996. с.68- 80.
- Идз М. Д. Витамины и минеральные вещества.// АО «Комплект», СПб. 1995 .с 119.
- Burke А.Р., Tang A.L. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly // New Engl. J. Med. — 1997. — Vol. 336. — P. 1276−1282.
- Davies M.J. A macro and micro view of coronary vascular insult in ischemic heart disease // Circulation. — 1990. — Vol. 82, (Suppl. 3). — P. 1138−46.
- Davies M.J., Bland J.M., Hangartner J.R. ei al. Factors influencing the presence or absence of acute coronary artery thrombi in sudden ischemic death // Europ. Heart J. — 1989. — Vol. 10. — P. 203−208.
- Diaz M.N., Frei В., Vita J.A., Keaney J.F. Antioxidants and atherosclerotic heart disease // New Engl. J. Med. — 1997. — Vol. 337. — P. 408−416.
- Farb A., Burke A.P., Tang A.L. et al. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis and sudden coronary death // Circulation. — 1996. — Vol. 93. — P. 1354−1363.
- Farb A., Tang A.L. Coronary plaque erosion without rupture into a lipid core: a frequent cause of coronary thrombosis in sudden coronary death // Circulation. -1996.-Vol. 93.-P. 1354−1363.
- Fuster V. Mechanisms leading to myocardial infarction: insights from stud ies of vascular biology // Circulation. — 1994. — Vol. 90. — P. 2126−2146.
- Fuster V. Badimon J.J. Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes // New Engl. J. Med. — 2002. — Vol. 326. — P. 242−250, 310−318.
- Gupta S. Leatham E.W. Carrington D. et al. Elevated Chlamydia pneumo niae antibodies, cardiovascular events? And azithromycin in male survivors of myo cardial infarction // Circulation. — 1997. — Vol. 96. — P. 404−407.
- Gurfinkel E., Bozovich G" Daroca A. et al. Randomised trial of roxithro- mycine in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Pilot Study Group // Lancet. — 1997. — Vol. 350. — P. 404−407.
- Hansson G.K., Jonasson L., Lojsthed B. et al. Localization of T lympho cytes and macrophages in fibrous and complicated human atherosclerotic plaques // Atherosclerosis. — 1988. — Vol. 72. — P. 153−141.
- Kullo I J., Edwards W.D., Schwartz R.S. Vulnerable plaque: pathobiology and clinical implications//Ann. Inter. Med. — 1998.-Vol. 129.-P. 1050−1050.
- Libby P. Molecular basis of the acute coronary syndromes // Circulation. — 1995.-Vol. 91.-P. 2844−2850.
- Morrow D., Ridker P.M. Inflammation in cardiovascular disease // Text book ofCardiovascular Medicine / Ed. E. Topol. — Update. Vol. 2. — 1999. — P. 1−12.
- Richardson P.D., Davies M.J., Born J.V. Influence of plaque configuration and stress distribution on Assuring of coronary atherosclerotic plaques // Lancet. — 1999.-Vol. 2.-P. 941−944.
- Ridker P.M. Role of inflammation in the development of atherosclerosis. Implications for clinical medicine // Europ. Heart J. — 2003. — Vol. 2, (Suppl. D). — P. D57−59.
- Ridker P.M., Buring J.E., Shih J. et al. Prospective study of C-reactive pro tein and the risk of future cardiovascular events among apparently healthy women // Circulation. — 1998. — Vol. 98. — P. 731−733.
- Ridker P.M., Cushman M., Stampfer M.J. et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men // New Engl. J. Med. — 1997.-Vol. 336. — P. 973−979.
- Rimm E.B., Stampfer M.J., Ascherio A. et al. Vitamin E consumption and the risk of coronary heart disease in men //New Engl. J. Med.- 1993.-Vol. 328.-P. 1450−1456.
- Ross R. Atherosclerosis — an inflammatory disease // New Engl. J. Med. — 1999.-Vol. 340.-P. 115−126.
- Stephens N.G. Parsons A., Schofield P.M. et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study // 1.ancet. — 1996. — Vol. 347. — P. 781 -786.
- Toschi V., Gallo R., Lettino M, Fallon J. Tissue factor predicts the throm- bogenicity of human atherosclerotic components//Circulation. — 1997.-Vol. 95.-P. 594−599.
- VaughanC.J., Murphy M.B., Buckley B.M. Statins do more than just lower ing holesterol // Lancet. — 1996. — Vol. 348. — P. 1079−1082.
- Yusuf S., Pepine C.J., Garces C. et al. Effect of enalapril on myocardial in farction and unstable angina in patients with low ejection fractions // Lancet. — 1992. — Vol.340. -P. 1173−1178.
- Stampfer M. G ., Malinow M R. Willen W K. A prospective study of plasma homocysteine and risk myokardial infarction in US physicians JAMA 1992- 268- p 877−81
- Clarke R, Daly L., Robinson K. et al. Hyperhomocysteinemia: an inde pendent risk faktor for vaskular disease. N Engl J Med 1991- 324. p 1149−55.
- Boers G H, Smals A G., Trijbels F. G., et al. Heterozygosity for homocys- teinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med !985−3!3.p 709−15.
- Nygard O. Nordrehaug J.E. Refsum H., et al. Plasma homocysteine levels and mortality in pacients with coronary artery disease. N Engl J Med 1997- 337. p230- 36.
- Boushey C. J., Beresford S. A., Omenn G. S., et al. A quantitative assess- mennt of plasma homocysteine as a risk faktor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995- 274. p 1049−57.
- Meade T.W., Rudock V., Stirling Y., et al. Fibrinolytic activity, clotting fac tors, and long-term incidence of ischaemic heart disease in the Northwic Park Hert Study. Lancet 1993- 342. p 1076−9.
- Heinrich J., Baileisen L., Schulte K. et al. Fibrinogen and factor VII in the prediction of coronare risk. Results from the PRO-CAM study in healthy men. ArteriosclerThromb 1994- 14.54−9.
- Emst E ., Resch K.L. Fibrinogen as cardiovascular risk factor: a meta analysis and review of the literature. Ann Jntem Med 1993- 1 IS. p 956−63.
- Montalescot G., Ancri A., Vicaunt E., et al. Fibrinogen after coronary an gioplasty as a risk faktor for restenosis. Circulation 1995- 92. p 31−8.
- Smith E.B., Thompson W. D. Fibrin as a faktor in atherogenesis. Thromb Res 2000- 73. p 1−19.
- Koenig W., Hoffrneister H.C.A., Nehmer C, et al. How do fibrates lower fi brinogen? The possible role of interleukin-6 supression Abstract. Blod Coagul Fibri- nolisis2004−5Suppl2: 16.
- Verhoef P, Stampfer MJ. Epidemiology of vascular and thrombotic associa tions. In: Carmel R, Jacobsen DW, eds. //Homocysteine in health and disease. Cam bridge, UK: Cambridge University Press, 2001: p.357−70.
- Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative as sessment of plasma homocysteine as a risk factor for vascular disease. Probable bene fits of increasing folic acid intakes see comments.//JAMA I995−274:p. 1049−57.
- Clarke R, Stansbie D. Assessment of homocysteine as a cardiovascular risk factor in clinical practice.// Ann Clin Biochem 2001 -38:p.624−32.
- Rasmussen K., Moller J. Total homocysteine measurement in clinical prac tice. //Ann Clin Biochem 2000−37 (Pt 5):p.627−48.
- Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease.// Ann Rev Med 1998−49:p.31−62.
- Guttormsen AB, Schneede J. Fiskerstrand T, Ueland PM, Refsum FIM. Plasma concentrations of homocysteine and other aminothiol compounds are related to food intake in healthy human subjects. //J Nutr 1994- 124: pЛ 934−41.
- Ubbink JB, Vermaak WJ, van der Merwe A. Becker PJ. The effect of blood sample aging and food consumption on plasma total homocysteine levels.// Clin Chim Acta 1992−207:p.l 19−28.
- Rasmussen K, Mailer J, Lyngbak M. Within-person variation of plasma homocysteine and effects of posture and tourniquet application.// Clinical Chemistry 1999−45:p.l850−5.
- A!-Khafaji F, Bowron A, Day AP, Scott J, Stansbie D. Stabilization of blood homocysteine by 3-deazaadenosine. //Ann Clin Biochem 1998−35:p.780−2.
- Andersson A, Isaksson A, Hultberg B. Homocysteine export from erythrocytes and its implication for plasma sampling,// Clin Chem 1992:38:p.l311−5.
- Duarte NL, Wang XL, Wilcken DE. Effects of anticoagulant and time of plasma separation on measurement of homocysteine.// Clin Chem 2002−48:p.665−8.
- Moller J. Rasmussen K, Chnstensen L. External quality assessment of methylmalonic acid and total homocysteine.//Clinical Chemistry 1999:45:p.l536−42.
- Probst R, Brandl R, Blumke M, Neumeier D. Stabilization of homocysteine concentration in whole blood.// Clin Chem 1998−44:p. 1567−9.
- Vester B, Rasmussen K. High performance liquid chromatography method for rapid and accurate determination of homocysteine in plasma and serum.// Eur J Clin Chem & Clin Biochem 1991−29:p.549−54.
- Willems HP, Bos GM, Gerrits WB, den Heijer M. Vloet S, Blom HJ. Acidic citrate stabilizes blood samples for assay of total homocysteine. W Clin Chem 1998−44:p.342−5.
- Woltersdorf WW, Bowron A, Day AP, Scott J, Stansbie D. Abbott IMx homocysteine assay: significant interference by 3-deazaadenosine letter.// Ann Clin Biochem 1999−36 (Pt 4):p.533−542.
- Nauck M, Bisse E. Nauck M, Wieland H. Pre-analytical conditions affecting the determination of the plasma homocysteine concentration.// Clin Chem Lab Med 2001−39:p.675−80.
- Clarke R, Woodhouse P, Ulvik A, Frost С Sherliker P, Refsum H. Variability and determinants of total homocysteine concentrations in plasma in an elderly population.// Clin Chem 1998−44:p.!02−7.
- Cobbaert C, Arentsen JC, Mulder P, Hoogerbrugge N, Lindemans J. Significance of various parameters derived from biological variability of lipoprotein (a), homocysteine, cysteine, and total antioxidant status. //Clin Chem 1997−43:p.l958−64.
- Garg UC, Zheng ZJ, Folsom AR. Moyer YS, Tsai MY, McGovem P, Eck- feldt JH. Short-term and long-term variability of plasma homocysteine measurement. //Clin Chem 1997−43:p.l41−5.
- Rasmussen K, M0ller J, Lyngbak M, Pedersen AM, Dybkjaer L. Age- and gender-specific reference intervals for total homocysteine and methylmalonic acid in plasma before and after vitamin supplementation.// Clin Chem 1996:42:p.630−6.
- Rossi E, Beilby JP, McQuillan BM. Hung J. Biological variability and reference intervals for total plasma homocysteine.//Ann Clin Biochem 1999−36:p.56−61.
- Fraser CG, Hyltoft Petersen P, Libeer JC, Ricos С Proposals for setting generally applicable quality goals solely based on biology.// Ann Clin Biochem 1997−34:p.8-I2.
- Ueland PM, Refsum H. Stabler SP, Malinow MR. Andersson A. Allen RH. Total homocysteine in plasma or serum: methods and clinical applications.// Clin Chem !993−39:p. 1764−79.
- Pfeiffer CM, Huff DL, Smith SJ, Miller DT, Gunter EW. Comparison of plasma total homocysteine measurements in 14 laboratories: an international study.// Clinical Chemistry 1999−45:p.l261−8.
- Krijt J, Vackova M, Kozich V. Measurement of homocysteine and other aminothiols in plasma: advantages of using tris (2-carboxyethyl)phosphine as reductant compared with tri-n-butylphosphine.//Clin Chem 2001,47:p.lS21-S.
- Gilfix 8M, Blank DW, Rosenblatt DS. Novel reductant for determination of total plasma homocysteine.// Clin Chem I997−43:p.687−8.
- Stabler SP. Lindenbaum J, Savage DG. Allen RH. Elevation of serum cystathionine levels in patients with cobalamin and folate deficiency.// Blood 1993:81:p.3404−13.
- Rasmussen, Karsten and Mailer, Jan. Measurement of homocysteine in plasma: Experience with the GC-MS method. //Irish Journal of Medical Science 1995. 164.p.I5-i6.
- Pietzsch J, Julius U, Hanefeld M. Rapid determination of total homocysteine in human plasma by using N (O.S)-ethoxycarbonyl ethyl ester derivatives and gas chromatography-mass spectrometry.// Clin Chem 1997−43:p.2001−4.
- Shinohara Y, Hasegawa H, Tagoku K, Hashimoto T. Simultaneous determination of methionine and total homocysteine in human plasma by gas chromatography-mass spectrometry. //J Chromatogr В Biomed Sci Appt 2001:758:p.283−8.
- Magera MJ, Lacey JM, Casetta B, Rinaldo P. Method for the determination of total homocysteine in plasma and urine by stable isotope dilution and electrospray tandem mass spectrometry.// Clin Chem 1999−45:p. 1517−22.
- Gempel К, Gerbitz KB, Casetta B, Bauer MF. Rapid determination of total homocysteine in blood spots by liquid chromatography-electrospray ionization- tandem mass spectrometry. //Clin Chem 2000−46:p. 122−3.
- Andersson A, Brattstrom L. Isaksson A. Israelsson B, Hultberg B. Determination of homocysteine in plasma by ion-exchange chromatography.// Scand J Clin 1. ab Invest 1989−49:p.445−9.
- Andersson A, Isaksson A, Brattstrom L, Hultberg B. Homocysteine and other thiols determined in plasma by HPLC and thiol-specific postcolumn derivatiza- tion. //Clin Chem 1993−39:p.l590−7.
- Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. //J Chromatog 1987−422:p.43−52.
- Imai K, Toyo’oka T, Watanabe Y. A novel fluorogenic reagent for thiols: ammonium 7-f!uorobenzo-2-oxa-l, 3-diazole-4-sulfonate.// Anal Biochem 1983−128:p.47l-3.
- Ubbink JB, Hayward Vermaak WJ. Bissbort S. Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum.// J Chromatogr 199I-565:p.441−6.
- Pfeiffer CM, Huff DL, Gunter EW. Rapid and accurate HPLC assay fot plasma total homocysteine and cysteine in a clinical laboratory setting.// Clinical Chemistry 1999−45:p.290−2. ill
- Dias VC, Bamforth FJ, Tesanovic M, Hyndman ME, Parsons HG, Cem- browski GS. Evaluation and intermethod comparison of the Bio-Rad high- performance liquid chromatographic method for plasma total homocysteine. //Clin Chem 1998−44:p.2199−201.
- Donnelly JG, Pronovost С Evaluation of the Abbott IMx fluorescence polarization immunoassay and the bio-rad enzyme immunoassay for homocysteine: comparison with high-performance liquid chromatography.// Ann Clin Biochem 2000−37(Pt2):p.l94−8.
- Ducros V, CanditoM, Causse E, Couderc R, Demuth K, Diop ME et at. Comparison of plasma total homocysteine determinations in 9 french hospital laboratories by using 6 differents methods.// Ann Biol CHn (Paris) 2002−60:p.421−8.
- Yu KH, Joubran R, Asmi M, LawT, Spencer A, JoumaM, Rifai N. Agreement among four homocysteine assays and results in patients with coronary atherosclerosis and controls.// Clin Chem 2000−46:p.258−64.
- Zhang M, Gunter EW, Pfeiffer CM. Evaluation of the Drew Scientific ds30 homocysteine assay in comparison with the Centers for Disease Control and prevention reference HPLC method. //Clin Chem 200!-47:p.966−7.
- Malinow MR. Kang SS, Taylor LM, Wong PW, Coull B, Inahara T et al. Prevalence of hyperhomocyst (e)inemia in patients with peripheral arterial occlusive disease. //Circulation 1989−79:p.l 180−8.
- Evrovski J, Callaghan M, Cole DE. Determination of homocysteine by HPLC with pulsed integrated amperometry.// Clin Chem 1995−41:p.757−8.
- D’Eramo JL, Finkelstein AE, Boccazzi FO, Fridman O. Total homocysteine in plasma: high-performance liquid chromatographic determination with electrochemical detection and glassy carbon electrode. Ill Chromatogr В 1998−720:p.205−10.
- Martin SC, Tsakas-Ampatzis I, Bartlett WA, Jones AF. Measurement of plasma total homocysteine by HPLC with coulometric detection.// Clinical Chemistry 1999−45:p.l50−2.
- Pasas SA, Lacher NA, Davies Ml, Lunte SM. Detection of homocysteine by conventional and microchip capillary electrophoresis/electrochemistry.// Electrophoresis 2002−23:p.759−66.
- Shipchandler MT, Moore EG. Rapid, fully automated measurement of plasma homocyst (e)ine with the Abbott IMx analyzer.// Clin Chem 1995−41:p.991−4.
- Refsum H, Helland S, Ueland PM. Radioenzymic determination of homocysteine in plasma and urine.// Clin Chem 1985−3I:p.624−8.
- Frantzen F, Faaren AL, Alfheim I, Nordhei AK. Enzyme conversion immunoassay for determining total homocysteine in plasma or serum.// Clin Chem 1998−44:p.311−6.
- Nexo E, Engbaek F, Ueland PM, Westby C, O’Gorman P, Johnston С et al. Evaluation of novel assays in clinical chemistry: quantification of plasma total homocysteine.// Clin Chem 2000−46:p.l 150−6.
- Blanco-Vaca F, Arcelus R, Gonzalez-Sastre F. Ordonez-Llanos J, Queralto- Compano JM. Comparison of the Abbott IMx and a high-performance liquid chromatography method for measuring total plasma homocysteine.// Clin Chem Lab Med 2000−38:p.327−9.
- Brunelli T, Pepe G, Marcucci R, Giusti B, Prisco D, Abbate R, Fedi S. Comparison of three methods for total homocysteine plasma determination.// Clin Lab 2001−47:p.393−7.
- Chadefaux B, Coude M, Hamet M, Aupetit J. Kamoun P. Rapid determination of total homocysteine in plasma. //Clin Chem 1989−35:p.2002−9.
- Leino A. Fully automated measurement of total homocysteine in plasma and serum on the Abbott IMx analyzer. //Clinical Chemistry 1999−4:p.569−71.
- Mansoor MA. Comparison of Abbott IMx total homocysteine assay with a high pressure liquid chromatography method for the measurement of total homocysteine in plasma and serum from a Norwegian population.// Scand J Ciin Lab Invest 1999−59:p.369−74.
- Pfeiffer CM, Twite D. Shih J, Holets-McCormack SR, Gunter EW. Method comparison for total plasma homocysteine between the Abbott IMx Analyzer and an HPLC assay with internal standardization. //Clinical Chemistry 1999−45:p.152−3.
- Ubbink JB, Delport R. Riezler R. Vermaak WJH. Comparison of three dif ferent plasma homocysteine assays with gas chromatography-mass spectrometry. //Clinical Chemistry 1999−45:p.670−5.
- Wu AH, Holtman V, Apple FS, Ricchiuti V, DiBello PM, Jacobsen D. Mul- ticenter analytical evaluation of an automated immunoassay for total plasma homocys teine. //Ann Clin Lab Sci 2000−30:p. 185−90.
- Zighetti ML, Chantarangkul V, Tripodi A, Mannucci PM, Cattaneo M. De termination of total homocysteine in plasma: comparison of the Abbott IMx immunoassay with high performance liquid chromatography.// Haematologica 2002−87:p.89−94.
- Pemet P. LasnierE, Vaubourdolle M. Evaluation of the AxSYM homocys teine assay and comparison with the IMx homocysteine assay.// Clin Chem 2000−46:p.l440-l.
- Donnelly, J. G., Chen ML, and Gayle K. Comparison of the DPC lmmulite 2000 and Abbott IMx homocysteine methods. //Clin Chem 2002.48S6., p.112.
- Mindicino HJ, Carlsen J, Aagaard O, and Kaplan I. An evaluation of a Cen taur method on the Advia Centaur system. Clin Chem 2002.48S6., p.86.
- Rosenberg 1H. Is it time to standardize and to measure blood homocysteine levels in patients with heart disease? Am J Med 2002−112:582−3.
- Amadottir M, Hultberg B, Nilsson-Ehle P, Thyseli H. The effect of reduced glomerular filtration rate on plasma total homocysteine concentration.// Scand J Clin 1. ab Invest. 1996−56:p.41−46.
- Amadottir M, Hultberg B. Treatment with high-dose folic acid effectively lowers plasma homocysteine concentration in eye losporine-treated renal transplant re cipients. //Transplantation, 1997-t5:p.l087.
- Arnesen E. Refsum H, Bonaa KH, Ueland PM, Forde OH. Nordrehaung JE. Serum total homocysteine and coronary heart disease.// Int. J. Epidemiol. 1995−24:p.704−709.
- Bachmann J, Tepel M, Raidt H, Riezler R. Graefe U, Langer K, Zidek W Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients.// J.Am. Soc. Nephrol. 1995−6:p.I21-I25.
- Beaulieu AJ. Enhanced reduction of fasting total homocysteine levels with suprephysiological versus standard multivitamin dose folic acid supplementation in renal transplant patients.// Arteriosclerosis Thrombosis Vase Biol, 1999- 19: p.2918−21.
- Beynon JH, Pathy MSJ. An open, parallel group comparison of quinapril and captopril, when added to diuretic therapy, in the treatment of elderly patients with heart failure.// Curr Med Res Opin 1997- 13: p. 583−92.
- BiomHJ. Consequences of homocysteine export and oxidation in the vascu lar system. //Seminars in Thrombosis and Haemostasis, 2000:26:p.227−32.
- Bostom AG, Culleton B. Hyperhomocysteinaemia in chronic renal dis ease.// J Am Soc Nephrol, 1999- 10: p.891 -900.
- Bostom AG. Gohh RY, Beaulieu AJ, Nadeau MR. Hume AL. Jacques PF, Selhub J, Rosenberg IH. Treatment of hyperhomocysteinemia in renal transplant recipients: a randomized, placebo-controlled trial.// Ann. Intern. Med. 1997−127:p.l089-l092.
- Bostom AG, Roubenoff R, Dellaripa P, Nadeau MR, Sutherland P, Wilson PW. Jacques PF, Selhub J, Rosenberg IH. Validation of abbreviated oral methionine- loading test. //Clin Chem. 1995−41:p.948−949.
- Bostom AG, Shemin D. Lapane KL. Hume AL, Yoburn D, Nadeau MR, Bendich A, Selhub J. Rosenberg IH. High dose-B-vitamin treatment of hyperhomo cysteinemia in dialysis patients.//Kidney Int. I996−49:lp.47−152.
- Bots ML, Launer LJ, Lindemans J, Hofman A, Grobbee DE. Homocysteine, atherosclerosis and prevalent cardiovascular disease in the elderly: the Rotterdam Study. //J Intern Med. 1997−242:p.339−347.
- BottoLD, Yang QH. 5,10-Methylenetetrahydrofolate reductase gene vari ants and congenital anomalies: A HuGE review.// Am J Epidemiology, 2000−151:p.862−77.
- Boushey CJ, Beresford SA, Omenn GS, Motuisky AG. A quantitative as sessment of plasma homocysteine as a risk factor for vascular disease. //JAMA. 1995−274:p.l0491057.
- Brattstrom L. Vitamins as homocysteine — lowering agents. // J. Nutr. — 1996.- 126. P. 1246−1280.
- Brattstrom L. Vitamins as homocysteine-lowering agents.// J Nutr. 1996−126:p.l276−1280.
- Cattaneo M. Hyperhomocysteinemia, Atherosclerosis and Thrombosis.// Thromb Haemost, 1999−81:p. 165−76.
- Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. //Thromb. Hemost. — 1999.- vol.81.- P. 65−76.
- Cossu M. Plasma homocysteine levels and C677T MTHFR gene polymorphism in stable renal graft recipients.//Transplantation Proceedings, 2001,33:p.l 156.
- Cravo M. Hyperhomocysteinemia in chronic alcoholism: Relations to folic acid and vitamins B6 and B12 status.// Nutrition, 2000−16:p.296−302.
- Currie 1С, Wilson YG, Scott J, Day A, Stansbie D, Baird RN, Lamont PM Tennant WG. Homocysteine: an independent risk factor for the failure of vascular intervention. // Br. J. Surg. 1996−83:p.l238−1241.
- Cuskelly GJ, McNulty H. Scott JM. Effect of increasing dietary folate on red-cell folate: implications for prevention of neural tube defects.// Lancet. 1996−347:p.657−659.
- Dalery K, Lussier-Cacan S, Selhub J, Davignon J. Latour Y, Genest J Jr. Homocysteine and coronary artery disease in French Canadian subjects: relation with vitamins B12. B6. pyridoxal phosphate, and folate.// Am J Cardiol. 1995:75:p.l 107- 1111.
- DaubnerSC, Matthews RG. Purification and properties of methylenetetra- hydrofolate reductase from pig liver. W J Biol Chem. 1982−257:p.l40−145.
- Dimeny RM. Cardiovascular disease after renal transplantation.// Kidney In ternational, 2002−61, Suppl 80: p. 78−84.
- DuclouxD. Prevalence, determinants, and clinical significance of hyperho- mocyst (e)inaemia in renal-transplant recipients.// Nephrol Dial Transplant, 1998−13:p.2890−3.
- Ducloux D. Serum total homocysteine and cardiovascular disease occur rence in chronic, stable renal transplant recipients: A prospective study.// J Am Soc Nephrology, 2000:11 :p. 134−7.
- Duel. PB, Malinow MR. Homocyst (e)inemia, and risk of atherosclerosis: a clinical approach to evaluation and management.// Endocrinologist. 1998−8:p.170−177.
- Durand P. Impaired homocysteine metabolism and atherothrombotic dis ease.// Lab Invest, 2001, 81 -p.645−72.
- Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure.// Arch Intern Med 1993- 153: p.937−42.
- Elijahu H. Mizrahi, D.W. Jacobsen, R.P. Fridland. Plasma Homocisteine: A nev risk factor for Alzheimers Disease ?// JMA J.- 2002. 4. P. 187−190
- Brouwer IA. Betaine supplementation and plasma homocysteine in healthy volunteers.// Arch Intern Med. 2000−160:p.2546−7.
- Schwab U. Betaine supplementation decreases plasma homocysteine con centrations but do not affect body weight, body composition, or resting energy expenditure in human subjects. //Am J Clin Nutr, 2002−76:p.961−7.
- Steenge GR. Betaine supplementation lowers plasma homocysteine in healthy men and women. 11} Nutrition. 2003−133:p.1291−5.
- Kritcbewsky SB. Kritchewsky D. Egg consumption and coronary heart dis ease: an epidemiologic overview.// J Am Coll Nutr, 2000:19:p.549−555.
- Vollset. Coffee and homocysteine. Am J Clin Nutrition, 2000−71:403−4.
- Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM. Homocys teine and ischemic heart disease: results of a prospective study with implications regarding prevention.// Arch Intern Med. 1998−158:p.862−867.
- WilckenDE, WangXL, Sim AS, McCredieRM. Distribution in healthy and coronary populations of methylenetetrahydrofolate reductase (MTHFR) C677T muta tion.// Arterioscler Thromb Vase Biol. 1996−16:p.878−882.
- Wilcken DE, Wilcken B, Dudman NP, Tyrrell PA. Homocystinuria: the ef fects of betaine in the treatment of patients not responsive to pyridoxine.// N Engl J Med. 1983 -309:p.448−453.
- Wrone EM. An MTHFR variant, homocysteine, and cardiovascular comor bidity in renal disease.//Kidney International. 200 l-60:p.l 106−13.
- Biasucci L.M., Liuzzo G., Colizzi C, Rizzello V. Clinical use of C-reactive protein for the prognostic stratification of patients with ischemic heart disease//Ital. Heart J. — 2001. — Vol. 2, № 3. — P. 164−171.
- Braunwald E. Shattuck Lecture. Cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities // New Engl. J. Med. — 1997. — Vol. 337.-P. 1360−1369.
- Casscells W., Hathorn В. David M. etal. Thermal detection of cellular infiltrates in living atherosclerotic plaques: possible implications of plaque rupture and thrombosis // Lancet. — 1996. — Vol. 347. — P. 1447−1449.
- Castelli W.P. Lipids, risk factors, and ischaemic heart disease // Atherosclerosis. — 1996.-Vol. 124(Suppl.).-P- 1−9.
- Cermak J., Key N.S., Bach R.R. et al. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor // Blood. — 1993. — Vol. 82. — P. 513−520.
- Danesh J., Collins R., Appleby P., Peto R. Association of fibrinogen. C- reactive protein, albumin, or leucocyte count with coronary heart disease // J.A.M.A. — 1998.-Vol. 279.-P. 1477−1482.
- Davies M.J. Acute coronary thrombosis — the role of plaque disruption and its initiation and prevention//Europ. HeartJ.- 1995. -Vol. 16(Sappl. L.).-P. 3−7.
- Erikssen G., Liestol K., Bjornholt J.V. et al. Erythrocyte sedimentation rate: a possible marker of atherosclerosis and a strong predictor of coronary heart disease mortality // Europ. Heart J. -2000. — Vol. 21. — P. 1614−1620.
- Ernst E., Koenig W. Fibrinogen and cardiovascular risk // Vase. Med. — 1997.-Vol. 2-P. 115−125.
- Folsom A.R., Wu K.K., Rosamond W.D. et al. Prospective study of hemo static factors and incidence of coronary heart disease. The Atherosclerosis Rise in Communities (AR1C) Study // Circulation. — 1997. — Vol. 96. — P. 1102−1108.
- Frink R.J. Chronic ulcerated plaques: New insights into the pathogenesis of acute coronary disease // J. Invas. Cardiology. — 1994. — Vol. 6. — P. 713−785.
- Galis Z.S., Muszynski M, Sukhova G.K. et al. Cytokine-stimulated human vascular smoth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion//Circ. Res.-1994.-Vol. 75.-P. 181−189.
- Goldstein J.A. Demetriou D., Grines C.L. et al. Multiple complex coronary plaques in patients with acute myocardial infarction // New Engl. J. Med. — 2000. — Vol. 343.-P. 915−922.
- Griselli M., Herbert J., Hutchinson W.L. et al. C-reactive protein and com plement are important mediators of tissue damage in acute myocardial infarction // J. Exp.Med.-1999.-Vol. 190.-P. 1733−1740.
- Lagrand W.K., Niessen H.W.M., Wolbink GJ. et al. C-reactive protein colocolizes with complement in human hearts during acute myocardial infarction // Circulation. — 1997. — Vol. 95. — P. 97−103.
- Libby P. Molecular bases of the acute coronary syndromes // Circulation. — 1995. — Vol. 91. — P. 2844−2850.
- Moreno P.R. Atherothrombosis: the global approach for a global disease. Pathophysiology of atherothrombosis. — Highlights monograph from an International expert meeting on atherombosis. — Milan, 1998. — 25 p.
- Pasceri V., Willerson J.T., Yeh E.T.H. С-reactive protein induces MCP-1 expression by endothelian cells // Europ. Heart J. — 2001. — Abstract Supplement 3. — P. 372.
- Pinderski H., OslundL.J., Hendrick C.C. et al. Interleukin-10 blocks atherosclerotic events in vin-o and in vivo II Arterioscler. Thromb. Vase. Biol. — 1999. — Vol. 19.-P. 2847−2853.
- Pober J.S., Cotran R.S. Cytokines and endothelial cells biology // Physiol. Rev. — 1990. -Vol. 70. — P. 427−451.
- Ritchie M.E. Nuclear factor kb is selectively and markedly activated in humans with unstable angina pectoris // Circulation. — 1998. — Vol. 98. — P. 1707−1713.
- Rosenfeld M.E., Yla-Herttuala S., Lipton B.A. et al. Macrophage colony- siimulating factor mRNA and protein in atherosclerotic lesions of rebbits and humans // Amer. J. Pathology. — 1992. — Vol. 140. — P. 291−300.
- Ross R. Atherosclerosis — an inflammatory disease//New Engl. J. Med. — 1999.-Vol. 340.-P. 115−126,
- Stefanadis C, Diamantopoulos L., Demellis J. et al. Heart production of atherosclerotic plaques and inflammation assessed by the acute phase proteins in acute coronary syndromes // J. Mol. Cel. Cardiology. — 2000. — Vol. 32. — P. 43−52.
- Stein MP., Edberg J. C, Kimberly R. P- et al. C-reactive protein binding to FcgRlIa on human monocytes and neutrophils is allele-specific // J. Clin. Invest. — 2000.-Vol. 105.-P. 369−376.
- Toschi V. Gallo R., Lettino M. et al. Tissue factor modulates the throm- bogenicity ofhuman atherosclerotic plaque // Circulation. — 1997. — Vol. 95. — P. 594- 599.
- Foley DP Influence of coronary vessel size on renarrowing process and late angiographic outcome after successful balloon angioplasty. Circulation, 1994−90:p.l239−51.
- Schnyder G. Effect of homocysteine-Sowering therapy on restenosis after percutaneous coronary intervention for narrowings in small coronary arteries. Am J Cardiology, 2003−9I:p.l265−9.
- Dimeny RM. Cardiovascular disease after renal transplantation. Kidney International, 2002−61, Suppl 80: p.7884.
- Ducloux D. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: A prospective study. J Am Soc Nephrology, 2000- 11: p. 134−7.
- Arnadottir M Hultberg B. Treatment with high-dose folic acid effectively lowers plasma homocysteine concentration in cyclosporine-treated renal transplant recipients. Transplantation, 1997-I5:p.l087.
- Ducloux D. Prevalence, determinants, and clinical significance of hyperho- mocyst (e)inaemia in renal-transplant recipients. Nephrol Dial Transplant, 1998−13:p.2890−3.
- Fernandez-Miranda С Plasma homocysteine levels in renal transplanted patients on cyclosporine or tacrolimus therapy: effect of treatment with folic acid. Clin Transplant, 2000−14:p.l 10−4.
- Bostom AG. Treatment of hyperhomocysteineemia in renal transplant recipients. A randomized, placebo-controlled trial. Ann Intern Med. !997−127:p.l089- 92.
- Beaulieu AJ. Enhanced reduction of fasting total homocysteine levels with suprephysiological versus standard multivitamin dose folic acid supplementation in renal transplant patients. Arteriosclerosis Thrombosis Vase Biol, I999:19:p.2918−21.
- Bostom AG Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipients. Kidney International, 2001−59. Suppl 78: p.246−252.
- Marcucci R Vitamin supplementation reduces the progression of atheroscle rosis innhyperhomocysteinemic renal-transplant recipients. Transplantation, 2003−75:p.l55I-5.
- Marcucci R High cysteine levels in renal transplant recipients with hyper homocysteinemia and 5,10-MTHFR polymorphism. Transplantation, 2001−71:p.746- 51.
- Cossu M. Plasma homocysteine levels and C677T MTHFR gene polymor phism in stable renal graft recipients. Transplantation Proceedings, 2001−33:p.l 156−8.
- Wrone EM. An MTHFR variant, homocysteine, and cardiovascular comor bidity in renal disease. Kidney International, 2001−60:p. 1106−13.
- Peterson J, Spence J. Vitamin and progression of atherosclerosis in hyper- homocyst (e)inemia.Lancet-1998-p.351:263.
- Hackham DG. What level of plasma homocyst (e)ine should be treated? Ef fects of vitamin therapy on progression of carotid atherosclerosis in patients with ho- mocyst (e)ine levels above and below 14 micromol/L. Am J Hypertens, 2000−13:p.l05−10.
- Spence JD. Ultrasound measurement of carotid plaque as surrogate outcome for coronary artery disease. Review. Am J Cardiology, 2002−89.p. 10−15.